These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis. Hindson J Nat Rev Gastroenterol Hepatol; 2023 Sep; 20(9):559. PubMed ID: 37553497 [No Abstract] [Full Text] [Related]
5. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Feagan BG; Hibi T; Tuttle JL; Klekotka P; Friedrich S; Durante M; Morgan-Cox M; Laskowski J; Schmitz J; D'Haens GR Gastroenterology; 2020 Feb; 158(3):537-549.e10. PubMed ID: 31493397 [TBL] [Abstract][Full Text] [Related]
6. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911 [TBL] [Abstract][Full Text] [Related]
7. Mirikizumab for the treatment of moderate to severe ulcerative colitis. Hanzel J; Ma C; Jairath V Immunotherapy; 2023 Oct; 15(15):1199-1208. PubMed ID: 37465925 [TBL] [Abstract][Full Text] [Related]
8. [Mirikizumab for ulcerative colitis]. Sievers LK; Schreiber S; Nitschmann S Inn Med (Heidelb); 2023 Dec; 64(12):1230-1231. PubMed ID: 37847261 [No Abstract] [Full Text] [Related]
9. Mirikizumab (Omvoh) for ulcerative colitis. Med Lett Drugs Ther; 2024 Mar; 66(1698):46-47. PubMed ID: 38466213 [No Abstract] [Full Text] [Related]
10. Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies. Chua L; Friedrich S; Zhang XC Clin Pharmacokinet; 2023 Oct; 62(10):1479-1491. PubMed ID: 37610533 [TBL] [Abstract][Full Text] [Related]
11. Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes. Magro F; Pai RK; Kobayashi T; Jairath V; Rieder F; Redondo I; Lissoos T; Morris N; Shan M; Park M; Peyrin-Biroulet L J Crohns Colitis; 2023 Oct; 17(9):1457-1470. PubMed ID: 37057827 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Sandborn WJ; Ferrante M; Bhandari BR; Berliba E; Hibi T; D'Haens GR; Tuttle JL; Krueger K; Friedrich S; Durante M; Arora V; Naegeli AN; Schmitz J; Feagan BG Clin Gastroenterol Hepatol; 2022 Jan; 20(1):105-115.e14. PubMed ID: 32950748 [TBL] [Abstract][Full Text] [Related]
13. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. Steere B; Schmitz J; Powell N; Higgs R; Gottlieb K; Liu Y; Jia B; Tuttle JL; Sandborn WJ; Sands BE; D'Haens G; Reinisch W; Krishnan V Clin Transl Gastroenterol; 2023 Jul; 14(7):e00578. PubMed ID: 36881820 [TBL] [Abstract][Full Text] [Related]
14. Failure of interleukin 13 blockade in ulcerative colitis. Tilg H; Kaser A Gut; 2015 Jun; 64(6):857-8. PubMed ID: 25804632 [No Abstract] [Full Text] [Related]